Group 1 - The core point of the news is that Haohai Biological Technology (688366.SH) announced that its controlling shareholder, Jiang Wei, is under investigation by the China Securities Regulatory Commission for insider trading, which is unrelated to the company's stock [1] - The investigation pertains solely to Jiang Wei as an individual and will not significantly impact the company's daily operations [1] - As of May 7, Haohai Biological's stock price was 53.17 yuan, with a market capitalization of 12.399 billion yuan [1] Group 2 - Haohai Biological is a technology innovation company focused on the research, production, and sales of medical devices and pharmaceuticals using biomedical materials and genetic engineering technology [3] - The company aims to provide innovative medical products through technological innovation and resource integration, gradually achieving import substitution in related pharmaceutical products [3] - As of 2023, Haohai Biological has completed industry restructuring in biomedical materials and has achieved leading advantages in four main business areas: ophthalmology, plastic surgery and wound care, orthopedics, and anti-adhesion and hemostasis [3] Group 3 - For Q1 2025, Haohai Biological reported a revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit attributable to shareholders of 90.3121 million yuan, down 7.41% year-on-year [3] - The company's basic earnings per share for the first quarter were 0.39 yuan [3] - As of May 7, the stock price of Haohai Biological had decreased by 0.21% [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司 2024年度已審財務報表》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年3月21日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士及黃明先生；及本公司之獨立非執行 董事為沈紅波先生、姜志宏先生、蘇治先生、楊玉社先生及趙磊先生。 * 僅供識別 上海昊海生物科技股份有限公司 已审财务报表 2024年度 ...